Literature DB >> 2350528

Influence of nicardipine on the pharmacokinetics and pharmacodynamics of propranolol in healthy volunteers.

D F Schoors1, I Vercruysse, G Musch, D L Massart, A G Dupont.   

Abstract

1. The influence of a single oral dose of nicardipine 30 mg on the pharmacokinetics and pharmacodynamics of propranolol 80 mg was investigated in twelve healthy volunteers. 2. Co-administration of nicardipine significantly increased the AUC and the mean Cmax of propranolol. 3. Blood pressure and heart rate tended to decrease more when propranolol and nicardipine were administered together than when propranolol was given alone, but differences are of doubtful significance. 4. The results indicate that nicardipine alters the pharmacokinetics of propranolol by impaired hepatic 'first-pass' clearance, but pharmacodynamics were little affected.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2350528      PMCID: PMC1380147          DOI: 10.1111/j.1365-2125.1990.tb03671.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  16 in total

1.  Enhancement of the bioavailability of propranolol and metoprolol by food.

Authors:  A Melander; K Danielson; B Scherstén; E Wåhlin
Journal:  Clin Pharmacol Ther       Date:  1977-07       Impact factor: 6.875

2.  Effects of long-term combined dosing with nicardipine and propranolol on coronary hemodynamics, myocardial metabolism, and exercise tolerance in patients with angina pectoris: comparison with monotherapy.

Authors:  C Hanet; H Pouleur; B J Harlow; M F Rousseau
Journal:  Am Heart J       Date:  1988-08       Impact factor: 4.749

3.  Disposition of propranolol. V. Drug accumulation and steady-state concentrations during chronic oral administration in man.

Authors:  G H Evans; D G Shand
Journal:  Clin Pharmacol Ther       Date:  1973 Jul-Aug       Impact factor: 6.875

Review 4.  Calcium channel blocking agents in the treatment of cardiovascular disorders. Part II: Hemodynamic effects and clinical applications.

Authors:  P H Stone; E M Antman; J E Muller; E Braunwald
Journal:  Ann Intern Med       Date:  1980-12       Impact factor: 25.391

5.  Pharmacokinetic interaction between nifedipine and propranolol.

Authors:  E Zylber-Katz; M Turetz-Abramovitch; G Koren; M Levy
Journal:  Fundam Clin Pharmacol       Date:  1988       Impact factor: 2.748

6.  Changes in antipyrine and indocyanine green kinetics during nifedipine, verapamil, and diltiazem therapy.

Authors:  L A Bauer; M Stenwall; J R Horn; R Davis; K Opheim; L Greene
Journal:  Clin Pharmacol Ther       Date:  1986-08       Impact factor: 6.875

Review 7.  Nicardipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, in the treatment of angina pectoris, hypertension and related cardiovascular disorders.

Authors:  E M Sorkin; S P Clissold
Journal:  Drugs       Date:  1987-04       Impact factor: 9.546

8.  Effects of nicardipine or nifedipine added to propranolol in patients with coronary artery disease.

Authors:  H Pouleur; J Etienne; H Van Mechelen; C Van Eyll; A A Charlier; L A Brasseur; M F Rousseau
Journal:  Postgrad Med J       Date:  1984       Impact factor: 2.401

9.  Isolation of basic drugs from plasma using solid-phase extraction with a cyanopropyl-bonded phase.

Authors:  G Musch; D L Massart
Journal:  J Chromatogr       Date:  1988-11-18

10.  Objective assessment of antianginal treatment: a double-blind comparison of propranolol, nifedipine, and their combination.

Authors:  P Lynch; H Dargie; S Krikler; D Krikler
Journal:  Br Med J       Date:  1980-07-19
View more
  10 in total

1.  Nicardipine does not influence the pharmacokinetics and pharmacodynamics of atenolol.

Authors:  I Vercruysse; D F Schoors; G Musch; D L Massart; A G Dupont
Journal:  Br J Clin Pharmacol       Date:  1990-09       Impact factor: 4.335

Review 2.  Pharmacokinetic Variability of Drugs Used for Prophylactic Treatment of Migraine.

Authors:  Peer Tfelt-Hansen; Frederik Nybye Ågesen; Agniezka Pavbro; Jacob Tfelt-Hansen
Journal:  CNS Drugs       Date:  2017-05       Impact factor: 5.749

3.  The interactions between nisoldipine and two beta-adrenoceptor antagonists--atenolol and propranolol.

Authors:  H L Elliott; P A Meredith; C McNally; J L Reid
Journal:  Br J Clin Pharmacol       Date:  1991-09       Impact factor: 4.335

Review 4.  Clinical pharmacokinetics of calcium antagonists. An update.

Authors:  J G Kelly; K O'Malley
Journal:  Clin Pharmacokinet       Date:  1992-06       Impact factor: 6.447

Review 5.  Calcium antagonists. Drug interactions of clinical significance.

Authors:  T Rosenthal; D Ezra
Journal:  Drug Saf       Date:  1995-09       Impact factor: 5.606

6.  The pharmacodynamics and pharmacokinetics of the combination of nifedipine and doxazosin.

Authors:  R Donnelly; H L Elliott; P A Meredith; C A Howie; J L Reid
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

7.  Increase in plasma propranolol caused by nicardipine is dependent on the delivery rate of propranolol.

Authors:  I Vercruysse; D L Massart; A G Dupont
Journal:  Eur J Clin Pharmacol       Date:  1995       Impact factor: 2.953

8.  Influences of the calcium antagonists nicardipine and nifedipine, and the calcium agonist BAY-K-8644, on the pharmacokinetics of propranolol in rats.

Authors:  I Vercruysse; D F Schoors; D L Massart; A G Dupont
Journal:  Cardiovasc Drugs Ther       Date:  1993-08       Impact factor: 3.727

9.  Influence of CYP2D6-dependent metabolism on the steady-state pharmacokinetics and pharmacodynamics of metoprolol and nicardipine, alone and in combination.

Authors:  M A Laurent-Kenesi; C Funck-Brentano; J M Poirier; D Decolin; P Jaillon
Journal:  Br J Clin Pharmacol       Date:  1993-12       Impact factor: 4.335

10.  Development and Evaluation of a Physiologically Based Pharmacokinetic Drug-Disease Model of Propranolol for Suggesting Model Informed Dosing in Liver Cirrhosis Patients.

Authors:  Muhammad Nasir Kalam; Muhammad Fawad Rasool; Faleh Alqahtani; Imran Imran; Asim Ur Rehman; Naveed Ahmed
Journal:  Drug Des Devel Ther       Date:  2021-03-17       Impact factor: 4.162

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.